Castle Biosciences, a diagnostics company specializing in dermatologic and gastroenterological diseases, announced it will present a company overview at Baird's 2026 Global Healthcare Conference on September 15, 2026. The presentation will be available via live audio webcast on the company's website, with a replay accessible afterward. Additionally, Castle Biosciences will hold one-on-one investor meetings at the Lake Street Best Ideas Growth Conference on September 10, 2026. This event highlights the company's ongoing efforts to engage investors and showcase its innovative molecular tests that guide patient care.
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
CLPS Incorporation completed an AI-driven modernization of a 30-year-old mortgage loan system for a major international bank, reducing the project time from an estimated five years with 80 developers to just 16 months with 20 developers. The AI tool,...
FibroBiologics announced that IP Australia accepted their patent application for using cannabidiol combined with fibroblast-based cell therapy to treat degenerative disc disease. This approach aims to regenerate damaged spinal discs by protecting dis...
Sitka Gold Corp. has finalized its acquisition of the Clear Creek Property, completing its 100% ownership of the 447-square-kilometre RC Gold Project in Yukon. This property includes key deposits like Rhosgobel and targets currently under active dril...
Ramaco Resources announced new appointments in its Administration and Legal Departments, with Evan H. Jenkins taking on the role of Chief Administrative Officer overseeing key internal operations. Tyler Adkins was promoted to General Counsel, and Tyl...
